Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MDM2 | Q00987 | 16/20 | 0.59 |
| ▸ | TP53 | P04637 | 3/20 | 0.57 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | PKM | P14618 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.45 |
| ▸ | RAF1 | P04049 | 1/20 | 0.44 |
| ▸ | BRAF | P15056 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20100135 | 0.80 | MDM2 (0.72) | MDM2TP53ALDH1A1 | |
| SCHEMBL20100233 | 0.79 | MDM2 (0.60) | MDM2TP53ALDH1A1 | |
| SCHEMBL20100174 | 0.79 | MDM2 (0.60) | MDM2TP53ALDH1A1CYP2D6 | |
| SCHEMBL20100132 | 0.77 | MDM2 (0.61) | MDM2TP53 | |
| SCHEMBL20100138 | 0.76 | MDM2 (0.74) | MDM2 | |
| SCHEMBL20100134 | 0.76 | MDM2 (0.76) | MDM2TP53ALDH1A1CYP2D6 | |
| SCHEMBL20100137 | 0.76 | MDM2 (0.72) | MDM2TP53ALDH1A1 | |
| SCHEMBL20100152 | 0.76 | MDM2 (0.72) | MDM2TP53ALDH1A1CYP2D6CYP3A4 | |
| SCHEMBL20100123 | 0.75 | MDM2 (0.59) | MDM2TP53ALDH1A1RAF1BRAF | |
| SCHEMBL20100158 | 0.75 | MDM2 (0.62) | MDM2TP53ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10414726-B2 | Therapeutic agents | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2019-09-17 | — | — | US | disclosed |
| US-20180118684-A1 | THERAPEUTIC AGENTS | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2018-05-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180118684-A1 | THERAPEUTIC AGENTS | TP53, MDM2, TP53BP1 | MDM2 2/4885TP53 1/4885MEN1 1807/4885 |
| US-10414726-B2 | Therapeutic agents | TP53, MDM2, TP53BP1 | MDM2 2/4885TP53 1/4885MEN1 1807/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.